A pilot study of quality of life, mood, sleepiness and fatigue in patients with primary humoral immunodeficiency transitioning to subcutaneous immunoglobulin therapy

Documenti analoghi

• Evaluation of safety and efficacy of a 20% Subcutaneous Immunoglobulin (Hizentra™), after a dose equivalent switch from intravenous or subcutaneous replacement therapy in a cohort of primary immunodeficient patients
  di: Martin, Adriana, et al.
  Pubblicazione: (2012)
• Evaluation of safety and efficacy of a 20% Subcutaneous Immunoglobulin (Hizentra™), after a dose equivalent switch from intravenous or subcutaneous replacement therapy in a cohort of primary immunodeficient patients
  di: Martin Adriana, et al.
  Pubblicazione: (2012-11-01)
• Hyaluronidase facilitated subcutaneous immunoglobulin in primary immunodeficiency
  di: Jolles, Stephen
  Pubblicazione: (2013)
• Economic benefit of subcutaneous rapid push versus intravenous immunoglobulin infusion therapy in adult patients with primary immune deficiency
  di: Martin, Adriana, et al.
  Pubblicazione: (2012)
• Monosomy 22 with humoral immunodeficiency: is there an immunoglobulin chain deficit?
  di: García Miranda, J L, et al.
  Pubblicazione: (1983)